Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 14, showing 5 Applications out of 67 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s)

1.

21/06/16   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
1. Kenya Medical Research Institute, Kisumu Clinical Reseach Site (Kisumu county)
2. KEMRI/Walter Reed Project - Clinical Research Center, Kericho (Kericho county)
3. Ganjoni Clinic - University of Washington/University of Nairobi, Mombasa (Mombasa county)
4. Partners in Health Research and Development, Thika (Kiambu county)
5. KARGENO RESEARCH AND POLICY HUB (Kisumu county)
6. The Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) (Nairobi City county)
7. KEMRI-USAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
8. Moi University Clinical Research Centre (MUCRC), Chandaria Cancer and Chronic Diseases Center (CCCDC) (Uasin Gishu county)
9. Aga Khan University Hospital (Nairobi City county)
10. KEMRI CCR-Butere County Hospital Site (Kakamega county)
 
View

2.

ECCT/20/11/03   IMR-SCD-301
    A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease       
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
Site(s) in Kenya
1. Kenya Medical Research Institute-Kondele Children\'s Hospital (Kisumu county)
2. The Center For Respiratory Disease Research/KEMRI (Nairobi City county)
3. Gertrude\'s Children\'s Hospital (Nairobi City county)
 
View

3.

ECCT/23/03/04   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
 
View

4.

ECCT/24/04/04   TNBC
    A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF TOBEMSTOMIG/RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH   PEMBROLIZUMAB COMBINED WITH NABPACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1-POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. University of Nairobi - Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Nandi county)
3. The Aga Khan University Hospital - Kenya (Nairobi City county)
 
View

5.

ECCT/22/11/03   BFAST
    A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL)   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
View